ZFIN ID: ZDB-FIG-160630-32
Lovely et al., 2016 - Bmp signaling mediates endoderm pouch morphogenesis by regulating Fgf signaling in zebrafish. Development (Cambridge, England)   143(11):2000-11 Full text @ Development
ADDITIONAL FIGURES
PHENOTYPE:
Fish:
Conditions:
Observed In:
Stage: Day 5

Fig. 9

Bmp and Fgf signaling synergistically interact to achieve proper craniofacial development. Whole-mount images of 5dpf viscerocranium. (A-C) No gross craniofacial defects are present in wild-type or heterozygous controls (A), wild-type embryos treated with suboptimal doses of Dorsomorphin (B) or untreated fgf8a mutants (C). (D) Treating fgf8a mutants with suboptimal doses of Dorsomorphin causes severe craniofacial defects. (E,F) Similarly, wild-type or smad5 heterozygous embryos do not display any craniofacial defects (E), whereas these embryos treated with suboptimal doses of SU5402 (Pan-Fgf inhibitor, 10-18hpf) display minor hyomandibular defects (F, arrow). (G) Untreated smad5 mutants have characterized craniofacial defects (Swartz et al., 2011). (H) Suboptimal SU5402-treated smad5 mutants display severe craniofacial defects, including loss of ceratobranchial cartilages (arrowhead). (I-L) Severe craniofacial defects mirroring those of SU5402-treated smad5 mutants (see H) are present in smad5; fgf8a compound mutants (L) and not any other allelic combination (I-K). Ventral views, anterior to the left. Cartilages: Mc, Meckel′s; Ch, ceratohyal; Cb′s, ceratobranchial; Pq, palatoquadrate; HM, hyomandibular. Scale bar: 100┬Ám.

Gene Expression Details No data available
Antibody Labeling Details No data available
Phenotype Details
Fish Conditions Stage Phenotype
WT chemical treatment: dorsomorphin Day 5 embryonic viscerocranium morphogenesis process quality, normal
WT chemical treatment: SU5402 Day 5 hyosymplectic cartilage morphology, abnormal
fgf8ati282a/+ control Day 5 embryonic viscerocranium morphogenesis process quality, normal
fgf8ati282a/+ chemical treatment: dorsomorphin Day 5 embryonic viscerocranium morphogenesis process quality, normal
fgf8ati282a/ti282a control Day 5 embryonic viscerocranium morphogenesis process quality, normal
fgf8ati282a/ti282a chemical treatment: dorsomorphin Day 5 embryonic viscerocranium morphogenesis disrupted, abnormal
Day 5 pharyngeal arch cartilage morphology, abnormal
fgf8ati282a/ti282a ; smad5b1100/b1100 control Day 5 embryonic viscerocranium morphogenesis disrupted, abnormal
smad5b1100/+ control Day 5 embryonic viscerocranium morphogenesis process quality, normal
smad5b1100/+ chemical treatment: SU5402 Day 5 hyosymplectic cartilage morphology, abnormal
smad5b1100/+ ; fgf8ati282a/ti282a control Day 5 embryonic viscerocranium morphogenesis process quality, normal
smad5b1100/b1100 control Day 5 ceratohyal cartilage fused with ceratobranchial cartilage, abnormal
Day 5 embryonic viscerocranium morphogenesis disrupted, abnormal
Day 5 Meckel's cartilage decreased length, abnormal
smad5b1100/b1100 chemical treatment: SU5402 Day 5 ceratobranchial cartilage decreased amount, abnormal
Day 5 ceratohyal cartilage decreased size, abnormal
Day 5 ceratohyal cartilage fused with cartilage element, abnormal
Day 5 ceratohyal cartilage morphology, abnormal
Day 5 embryonic viscerocranium morphogenesis disrupted, abnormal
Day 5 Meckel's cartilage decreased size, abnormal
Day 5 Meckel's cartilage fused with cartilage element, abnormal
Day 5 Meckel's cartilage morphology, abnormal
smad5b1100/b1100 ; fgf8ati282a/+ control Day 5 ceratobranchial cartilage decreased amount, abnormal
Day 5 embryonic viscerocranium morphogenesis disrupted, abnormal
Day 5 pharyngeal arch cartilage morphology, abnormal
Acknowledgments:
ZFIN wishes to thank the journal Development (Cambridge, England) for permission to reproduce figures from this article. Please note that this material may be protected by copyright. Full text @ Development